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the biotech industry is the usual venue of new drug development, with costs estimat-ed between $500 million and $2 billion 
per drug developed (Adams and Brantner, 2006). 
Occasionally, members of an academic medi-
cal community may choose to develop a new 
drug within their own institution because they 
are focused on an orphan disease and/or their 
new therapy may lack a successful financial 
model. The Dermatology Department at Stanford 
University School of Medicine has focused on 
creating a successful treatment for epidermolysis 
bullosa since 1988. Support for this process has 
come from philanthropy (http://www.ebkids.org) 
as well as federal and state funding.
During this process, we have learned that 
most academic medical centers do not pre-
pare faculty for the challenges of developing 
new drugs. The focus of this Editorial and the 
Supplementary Material online is to review 
the process for beginning a clinical trial for a 
new drug product in the United States. Major 
goals include Investigational New Drug (IND) 
approval and completion of multiple clinical tri-
als, with a final goal of New Drug Application 
(NDA) approval, allowing the drug to be pre-
scribed, sold, and marketed within the United 
States (FDA, 2010a,b).
Drug development occurs in individual 
states, but because most drugs will eventually 
be shipped across state borders, they are under 
control of federal law, enforced by the US Food 
and Drug Administration (FDA) (FDA, 2010c). 
An IND is the FDA exemption that allows a 
drug to be shipped across state lines before the 
NDA is approved. IND submission follows ini-
tial studies that demonstrate the drug’s safety 
in animals, with the goal of conducting human 
clinical studies to determine its therapeutic 
potential (FDA, 2010c).
During the process of obtaining an IND for 
gene transfer for epidermolysis bullosa, we 
have found that personal contact with the FDA 
during the concept stage allowed us to under-
stand the submission process and the FDA to 
understand our goals and capabilities. FDA 
regulations require precise actions, but the goal 
of the agency’s staff is to bring the best prod-
ucts to patients as soon as possible. FDA staff 
will inform you when formal correspondence is 
necessary and when they can answer your que-
ries without documentation. However, we rec-
ommend that you maintain a log of all contact 
with the FDA (including e-mail and telephone 
conversations), beginning with the first pre-IND 
communications. This log will help to prevent 
your repeating questions.
IND submission requires an application to 
either the Center for Biologics Evaluation and 
Research or the Center for Drug Evaluation 
and Research (Table 1; FDA, 2010d). Devices 
are regulated by a separate entity and require 
a different type of application, which is not 
discussed in this Editorial (FDA, 2010e). IND 
table 1.  Center for Biologics evaluation and research versus Center for drug evaluation research
Fda Center Products under center’s jurisdiction
Center for Biologics Evaluation and Research Cellular products composed of human, bacterial, or animal cells; 
gene therapy products; vaccines; allergenic extracts used for the 
diagnosis and treatment of allergic diseases; antitoxins, antiven-
ins, and venoms; and blood and blood components
Center for Drug Evaluation and Research Nonbiological drugs as well as monoclonal antibodies for in vivo 
use and proteins intended for therapeutic use, including cytokines, 
enzymes, growth factors, and immunomodulators
From FDA, 2010d.
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application requirements are available on the FDA’s website 
(FDA, 2010f)—check whether your institution has a program 
in place to assist with the logistics of this process. The IND 
application consists of four main parts, listed in the order in 
which they appear in the IND application: (i) Investigator’s 
Brochure (IB), (ii) Clinical Protocol, (iii) Chemistry, 
Manufacturing, and Control (CMC), and (iv) Pharmacology 
and Toxicology (FDA, 1995, 2000). INDs can be submitted 
in hard copy or electronically (FDA, 2002).
investigator’s Brochure
For single-site studies in which the investigator will hold the 
IND, the IB is not required (FDA, 2010g). Data from previous 
studies are included in the IB, which is important in deter-
mining whether an adverse event is considered “reportable” 
(FDA, 2009).
Clinical Protocol section
Clinical investigators will be most familiar with the Clinical 
Protocol. All human clinical trials require institutional review 
board (IRB) approval from the local institution. The clinical 
trial and recruitment efforts cannot begin until approval is 
granted, which is contingent on approval of the IND by the 
FDA. The local IRB can often help navigate FDA regulations. 
Each institution will most likely require completion of train-
ing requirements to work with human subjects in addition 
to Health Insurance Portability and Accountability Act train-
ing (FDA, 2010h; National Institutes of Health, 1949, 1979; 
Stanford University).
The Clinical Protocol describes the details of the clinical trial 
that will test the product. Clinical trials are divided into three 
phases: I, II, and III (Table 2; FDA, 2010a). The conduct of clin-
ical trials requires compliance with established international 
regulations known as “good clinical practices” (FDA, 2011a,b). 
For additional information on good clinical practices, includ-
ing adverse-event reporting, see the Supplementary Material 
online. As one prepares for a trial, it may be useful to consider 
hiring an outside contract research organization because the 
complexity of the regulations may require expertise that is not 
common within an academic institution.
Chemistry, Manufacturing, and Control section
The CMC section describes the chemical formulation of 
the drug, how it will be manufactured, and the requisite 
control of these processes (e.g., purity of reagents). During 
a pre-IND meeting with the FDA, investigators will have 
an opportunity to discuss the CMC and to determine the 
FDA’s specific requirements for the product. There are 
specific requirements for drug manufacturing called good 
manufacturing practice or current good manufacturing 
practice (FDA, 2004; 2010i,j; 2011c); however, current 
good manufacturing practice is not required for phase I clin-
ical trials (FDA, 2008). Instead, the CMC for a phase I trial 
focuses on identification and control of raw mater ials used 
to manufacture the drug, as well as the drug itself (FDA, 
2010f). There are also complex requirements for release 
criteria of the final product (FDA, 2010k). Laboratories used 
for testing should abide by regulations for good laboratory 
practices (FDA, 2010l). There are additional criteria for 
reagents of animal origin (US Department of Agriculture, 
2003), biohazardous agents, and recombinant DNA, as 
well as gene therapy, somatic cell therapy, and stem cell 
therapy (Carpenter et al., 2009; Fink, 2009). Please see the 
Supplementary Material for additional information about 
these special cases.
Pharmacology and toxicology section
The animal studies included in this section will vary wide-
ly, and they must be discussed with the FDA at the pre-IND 
meeting. Areas of special concern include studies involving 
stem cells and gene therapy. The Supplementary Material 
includes guidance about these topics.
Concluding comments
Although the process of applying for an IND may seem 
daunting, we hope that our suggestions have provided 
some clarification. We acknowledge that by the time this 
article is published, there may be additional changes to 
the IND submission process and even changes in the guid-
ance documents referenced in the supplementary material. 
However, the priority of patient safety will remain, and the 
FDA is, in fact, interested in the successful development of 
new therapies for patients.
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table 2. Phases of clinical trials 
Study phase Goal Subjects (characteristics, no. of subjects)
Phase I Determine the metabolic and pharmacologic actions of the drug. 
Determine side effects
Healthy volunteers or small number of patients
Phase II Obtain preliminary data on drug efficacy Small numbers of patients
Phase III Gather statistically significant information about efficacy and safety of a 
drug. This takes place after the preliminary evidence suggests efficacy. 
Results will provide a basis for extrapolating results to the general 
population and transmitting that information in the physician labeling 
package for the New Drug Application
Several hundred or more
From FDA, 2010a.
editorial
998 Journal of Investigative Dermatology (2011), Volume 131 
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
Emily S. Gorell1, Andrea L. Tichy1 and Alfred T. Lane1
1Department of Dermatology, Stanford School of Medicine, 
Redwood City, California, USA
Correspondence: Alfred T. Lane, 450 Broadway Street, Pavilion C, Redwood 
City, CA 94063, USA. E-mail: alfred.lane@stanford.edu
RefeReNceS
Adams CP, Brantner VV (2006) Estimating The cost of new drug development: 
is it really $802 million? Health Aff 25:420–8
Carpenter MK, Frey-Vasconcells J, Rao MS (2009) Developing safe therapies 
from human pluripotent stem cells. Nat Biotech 27:606–13
Fink DW (2009) FDA regulation of stem cell-based products. Science 
324:1662–3
FDA (1995). US Food and Drug Administration. Guidance for industry: 
content and format of Investigational New Drug Applications (INDs) 
for Phase 1 studies of drugs, including well-characterized, therapeutic, 
biotechnology-derived products. http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm071597.pdf
FDA (2000). US Food and Drug Administration. Guidance for industry: Q&A: 
content and format of INDs for Phase 1 studies of drugs, including well-
characterized, therapeutic, biotechnology-derived products. http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm078928.pdf
FDA (2002). US Food and Drug Administration. Guidance for 
industry: providing regulatory submissions to CBER in electronic 
format—Investigational New Drug Applications (INDs). 
h t t p : / / w w w. f d a . g ov / d ow n l o a d s / B i o l o g i c s B l o o d Va c c i n e s /
GuidanceComplianceRegulatoryInformation/Guidances/General/
UCM150028.pdf
FDA (2004). US Food and Drug Administration. Guidance for industry: 
sterile drug products produced by aseptic processing—current good 
manufacturing practice. http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm070342.pdf
FDA (2008). US Food and Drug Administration. Guidance for industry: cGMP 
for Phase 1 investigational drugs. http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm070273.pdf
FDA (2009). US Food and Drug Administration. Guidance for clinical 
investigators, sponsors, and IRBs: adverse event reporting to IRBs—
improving human subject protection. http://www.fda.gov/downloads/
RegulatoryInformation/Guidances/UCM126572.pdf
FDA (2010a). US Food and Drug Administration. Drug 
development and review definitions. http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/InvestigationalNewDrugINDApplication/
ucm176522.htm (accessed 21 January 2010)
FDA (2010b). US Food and Drug Administration. Types of applications. 
h t t p : / /www. fda . gov /Drug s /Deve lopmen tApp rova lP roce s s /
HowDrugsareDevelopedandApproved/ApprovalApplications/default.
htm (accessed 21 January 2010)
FDA (2010c). US Food and Drug Administration. Investigational 
New Drug (IND) application. http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/InvestigationalNewDrugINDApplication/default.
htm# (accessed 24 September 2010)
FDA (2010d). US Food and Drug Administration. Transfer of therapeutic 
products to the center for drug evaluation and research. http://www.
fda.gov/AboutFDA/CentersOffices/CBER/ucm133463.htm (accessed 24 
September 2010)
FDA (2010e). US Food and Drug Administration. Device advice: device 
regulation and guidance. http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/default.htm (accessed 24 September 
2010)
FDA (2010f). US Food and Drug Administration. Code of Federal Regulations 
Title 21, Part 312—Investigational New Drug Application. http://www.
accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.23 
(accessed 24 September 2010)
FDA (2010g). US Food and Drug Administration. Code of Federal Regulations: 
21 CFR 312.55: informing investigators. http://www.accessdata.fda.
gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.55 (accessed 29 
September 2010)
FDA (2010h). US Food and Drug Administration. Code of Federal 
Regulations, Title 45, Part 46: protection of human subjects. http://ohsr.
od.nih.gov/guidelines/45cfr46.html (accessed 10 March 2011)
FDA (2010i). US Food and Drug Administration. Code of Federal 
Regulations, Title 21, Part 210—current good manufacturing practice in 
manufacturing, processing, packing, or holding of drug; general. http://
www.access.gpo.gov/nara/cfr/waisidx_10/21cfr210_10.html (accessed 
24 September 2010)
FDA (2010j). US Food and Drug Administration. Code of Federal 
Regulations, Title 21, Part 211—current good manufacturing practice 
for finished pharmaceuticals. http://www.access.gpo.gov/nara/cfr/
waisidx_10/21cfr211_10.html (accessed 24 September 2010)
FDA (2010k). US Food and Drug Administration. Code of Federal 
Regulations, Title 21, Part 610—general biological products standards. 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.
cfm?CFRPart=610 (accessed 24 September 2010)
FDA (2010l). US Food and Drug Administration. Code of Federal Regulations, 
Title 21, Part 58: good laboratory practice for nonclinical laboratory studies. 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.
cfm?CFRPart=58 (accessed 24 September 2010)
FDA (2011a). US Food and Drug Administration. FDA regulations relating 
to good clinical practice and clinical trials. http://www.fda.gov/
ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm155713.htm# 
(accessed 25 January 2011)
FDA (2011b). US Food and Drug Administration. Running clinical trials. http://
www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/
default.htm (accessed 25 January 2011)
FDA (2011c). US Food and Drug Administration. Questions and answers 
on current good manufacturing practices (cGMP) for drugs. http://www.
fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm124740.htm (accessed 25 January 2011)
National Institutes of Health, Office of Human Subjects Research (1949) 
Nuremberg Code, Directives for Human Experimentation. http://ohsr.
od.nih.gov/guidelines/nuremberg.html
National Institutes of Health, Office of Human Subjects Research (1979) The 
Belmont Report. http://ohsr.od.nih.gov/guidelines/belmont.html
Stanford University, Office of the Dean of Research. Stanford University 
Human Research Protection Program (HRPP). http://humansubjects.
stanford.edu/hrpp/Chapter1.html (accessed 21 January 2010)
US Department of Agriculture (2003) Code of Federal Regulations—Title 9, 
Volume 1. http://www.access.gpo.gov/nara/cfr/waisidx_03/9cfr113_03.
html (accessed 24 September 2010)
